129 related articles for article (PubMed ID: 688252)
1. Lack of therapeutic synergism between vincristine and methotrexate in L1210 murine leukemia in vivo.
Bender RA; Nichols AP; Norton L; Simon RM
Cancer Treat Rep; 1978 Jul; 62(7):997-1003. PubMed ID: 688252
[TBL] [Abstract][Full Text] [Related]
2. Schedule-dependent synergism of methotrexate and vincristine against murine L1210 leukemia.
Chello PL; Sirotnak FM; Dorick DM; Moccio DM
Cancer Treat Rep; 1979; 63(11-12):1889-94. PubMed ID: 526921
[TBL] [Abstract][Full Text] [Related]
3. Increased schedule-dependent synergism of vindesine versus vincristine in combination with methotrexate against L1210 leukemia.
Chello PL; Sirotnak FM
Cancer Treat Rep; 1981; 65(11-12):1049-53. PubMed ID: 7296551
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and pharmacologic study of therapeutic synergism with cyclophosphamide plus methotrexate in murine L1210 leukemia.
Klubes P; Cerna I
Cancer Treat Rep; 1981; 65(1-2):107-14. PubMed ID: 7226161
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
[TBL] [Abstract][Full Text] [Related]
6. Analysis of "early" thymidine/inosine protection as an adjunct to methotrexate therapy.
Eleff M; Franks PE; Wampler GL; Collins JM; Goldman ID
Cancer Treat Rep; 1985; 69(7-8):867-74. PubMed ID: 2410122
[TBL] [Abstract][Full Text] [Related]
7. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture.
Kano Y; Ohnuma T; Okano T; Holland JF
Cancer Res; 1988 Jan; 48(2):351-6. PubMed ID: 3422052
[TBL] [Abstract][Full Text] [Related]
8. Different effects of vincristine on methotrexate uptake by L1210 cells and mouse intestinal epithelia in vitro and in vivo.
Chello PL; Sirotnak FM; Dorick DM
Cancer Res; 1979 Jun; 39(6 Pt 1):2106-12. PubMed ID: 445407
[No Abstract] [Full Text] [Related]
9. Improved therapeutic index with high-dose methotrexate: comparison of thymidine-purine rescue with citrovorum factor rescue in mice.
Samuels LL; Straw JA
Cancer Res; 1984 Jun; 44(6):2278-84. PubMed ID: 6609764
[TBL] [Abstract][Full Text] [Related]
10. Demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia.
Wampler GL; Carter WH; Campbell ED; Goldman ID
Cancer Treat Rep; 1987 Jun; 71(6):581-91. PubMed ID: 3581096
[TBL] [Abstract][Full Text] [Related]
11. Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells.
Capizzi RL
Cancer Treat Rep; 1981; 65 Suppl 4():115-21. PubMed ID: 7049375
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of DNA synthesis and enhancement of the uptake and action of methotrexate by low-power-density microwave radiation in L1210 leukemia cells.
Chang BK; Huang AT; Joines WT
Cancer Res; 1980 Apr; 40(4):1002-5. PubMed ID: 7357530
[TBL] [Abstract][Full Text] [Related]
13. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.
Sirotnak FM; Moccio DM; Dorick DM
Cancer Res; 1978 Feb; 38(2):345-53. PubMed ID: 304375
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological and therapeutic properties of carrier bound methotrexate against tumor confined to a third space body compartment.
Chu BC; Howell SB
J Pharmacol Exp Ther; 1981 Nov; 219(2):389-93. PubMed ID: 6974776
[TBL] [Abstract][Full Text] [Related]
15. Exchangeable intracellular methotrexate levels in the presence and absence of vincristine at extracellular drug concentrations relevant to those achieved in high-dose methotrexate-folinic acid "rescue" protocols.
Goldman ID; Gupta V; White JC; Loftfield S
Cancer Res; 1976 Jan; 36(1):276-9. PubMed ID: 1248006
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A
Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside.
Presant CA; Vietti TJ; Valeriote F; Coulter DM
J Natl Cancer Inst; 1981 Dec; 67(6):1283-8. PubMed ID: 6171666
[TBL] [Abstract][Full Text] [Related]
18. The influence of recombinant human tumor necrosis factor-alpha, alone and in combination with cyclophosphamide or methotrexate, on leukemia L1210 and normal hematopoiesis in mice.
Warzocha K; Robak T; Korycka A; Graczyk J; Pakulska W; Gałazka G; Kłysik J
Arch Immunol Ther Exp (Warsz); 1991; 39(5-6):587-95. PubMed ID: 1841555
[TBL] [Abstract][Full Text] [Related]
19. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388.
Góra-Tybor J; Robak T
Acta Haematol Pol; 1993; 24(2):177-82. PubMed ID: 8103959
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and pharmacokinetic effects of leucovorin after high-dose methotrexate in a murine leukemia model.
Sirotnak FM; Donsbach RC; Moccio DM; Dorick DM
Cancer Res; 1976 Dec; 36(12):4679-86. PubMed ID: 1087182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
